Our data is concordant with the results from cancer genomics database analysis which show that, among DNMT3A mutated MNs, the DNMT3A R882 mutations are mostly enriched in AML (67.5%, p<.001 by Fisher’s exact test); compared with 25% in MDS (p=.009 by Fisher’s exact test), and 12.5% in MPN (p=.06 by Fisher’s exact test) (Table 1). This evidence concerns the gene DNMT3A and myelodysplastic syndrome.